Lecanemab (brand name Leqembi; development code BAN2401) is a humanized IgG1 monoclonal antibody developed by Eisai and Biogen for the treatment of early Alzheimer's Disease. It represents a significant advancement in disease-modifying therapy for Alzheimer's Disease by targeting protofibrils of Amyloid-Beta (Aβ)[1]. Approved in 2023, Leqembi became the first amyloid-targeting antibody to receive traditional FDA approval based on Phase III clinical trial data.
Lecanemab binds with high affinity to soluble Aβ protofibrils, which are highly toxic intermediate aggregates in the amyloid cascade. Unlike earlier anti-amyloid antibodies that primarily targeted monomers or mature plaques, lecanemab's specificity for protofibrils allows it to intercept the most toxic form of Aβ before it can cause widespread neuronal damage[2].
The approval of lecanemab marked a paradigm shift in Alzheimer's treatment, demonstrating that removing amyloid plaques can slow cognitive decline in early-stage patients. This validation of the amyloid cascade hypothesis has spurred further development of anti-amyloid and anti-tau therapeutics.
Lecanemab's mechanism differs from other anti-amyloid antibodies:
The antibody-Aβ complex is cleared through multiple pathways[3]:
The Phase IIb trial enrolled 856 patients with early AD (MCI due to AD or mild AD dementia)[4]:
| Endpoint | Result |
|---|---|
| Primary (ADCOMS at 18 months) | Dose-dependent reduction observed |
| Brain amyloid reduction | Dose-dependent clearance |
| Highest dose (10 mg/kg biweekly) | Slower clinical decline |
This study established the optimal dosing regimen of 10 mg/kg biweekly for the Phase III program.
The Phase III Clarity-AD trial enrolled 1,795 patients with early AD[5]:
Lecanemab demonstrated clinically meaningful benefits:
| Biomarker | Change |
|---|---|
| Brain amyloid (Centiloid) | Reduced from 53 to 10 |
| CSF p-tau181 | Reduced significantly |
| CSF t-tau | Reduced significantly |
| Amyloid-related imaging abnormalities (ARIA) | Slight increase |
| ARIA Type | Lecanemab | Placebo |
|---|---|---|
| ARIA-E (edema) | 12.6% | 1.7% |
| ARIA-H (hemorrhage) | 17.3% | 9.0% |
Baseline: MRI within 6 months before first infusion, APOE testing recommended.
MRI Schedule: Week 12, Week 24, then annually. Additional scans if symptoms develop.
Risk Factors:
Monitoring Checklist:
| Feature | Lecanemab | Donanemab | Aducanumab |
|---|---|---|---|
| Target | Protofibrils | Plaques | Plaques/monomers |
| Dosing | 10 mg/kg biweekly | Variable | 10 mg/kg monthly |
| Amyloid reduction | ~80% | ~70% | ~60% |
| CDR-SB benefit | 0.45 | 0.70 | 0.39 |
| ARIA-E rate | 12.6% | 24% | 35% |
Early Alzheimer's Disease (MCI due to AD or mild dementia) with confirmed amyloid pathology via PET scan or CSF biomarkers.
Investigational approaches include:
The study of Lecanemab (Leqembi) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
McDade, E., et al. (2022). Lecanemab in patients with early Alzheimer's Disease: detailed results on biomarker, cognitive, and clinical efficacy. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12653 ↩︎
Ishii, M., et al. (2022). Lecanemab: A Novel Anti-Amyloid Monoclonal Antibody for Alzheimer's Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/JAD-220858 ↩︎
van Dyck, C.H., et al. (2023). Lecanemab in Early Alzheimer's Disease. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2212948 ↩︎
Cummings, J., et al. (2022). Lecanemab: A Review of Its Use in Alzheimer's Disease. Neurology and Therapy. https://doi.org/10.1007/s40120-022-00345-7 ↩︎
Eisai Co., Ltd. (2022). Lecanemab Clarity-AD Topline Results. Press Release. ↩︎
Sperling, R.A., et al. (2023). Amyloid-related imaging abnormalities in the Clarity-AD trial. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12795 ↩︎